Larimar Therapeutics, Inc. (LRMR) News

Larimar Therapeutics, Inc. (LRMR): $1.99

-0.11 (-5.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LRMR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 413

in industry

Filter LRMR News Items

LRMR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest LRMR News From Around the Web

Below are the latest news stories about Larimar Therapeutics Inc that investors may wish to consider to help them evaluate LRMR as an investment opportunity.

What Made LifeSci Capital Downgrade Larimar Therapeutics’ Stock?

In a report released yesterday, Patrick Dolezal from LifeSci Capital downgraded Larimar Therapeutics (LRMR – Research Report) to Hold, with a price target of $3.00. The company's shares closed last Tuesday at $4.01, close to its 52-week low of $2.71. According to TipRanks.com, Dolezal is ranked #7496 out of 7791 analysts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Larimar Therapeutics with a $8.00 average price target, a 162.3% upside from current levels. In a report released yesterday, William Blair also downgraded the stock to Hold. See Insiders’ Hot Stocks on TipRanks >> Larimar Therapeutics' market cap is currently $148.

Catie Powers on TipRanks | February 16, 2022

Larimar Therapeutics' stock plunges on FDA decision; could implement cost-cutting measures

The Food and Drug Administration dealt Larimar Therapeutics a setback when the agency decided to maintain its clinical hold on the Bala Cynwyd biotechnology company's effort to develop a treatment for a rare condition

Yahoo | February 16, 2022

Larimar Therapeutics Provides Update on CTI-1601 Clinical Program

BALA CYNWYD, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on Larimar’s CTI-1601 program. FDA stated it is maintaining its clinical hold at this time and that additional data is needed to resolve the clinical hold. Larimar is furt

Yahoo | February 14, 2022

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | January 19, 2022

Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference

BALA CYNWYD, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in virtual 1x1 investor meetings at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29, 2021 through December 2, 2021. About Larimar TherapeuticsLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage bio

Yahoo | November 22, 2021

In spite of Larimar Therapeutics, Inc.'s recent pullback, insiders still gained about US$85k after buying earlier this year.

Insiders who bought Larimar Therapeutics, Inc. ( NASDAQ:LRMR ) in the last 12 months may probably not pay attention to...

Yahoo | November 20, 2021

Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference

BALA CYNWYD, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the Guggenheim Virtual Neuro/Immunology Conference taking place November 15 – 16, 2021. About Larimar TherapeuticsLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on

Yahoo | November 15, 2021

Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results

BALA CYNWYD, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter and year to date September 30, 2021 operating and financial results. “We are advancing towards 2022 with a strong balance sheet, the backing of high-quality institutional investors, and compelling Phase 1 data that demonstrate proof-of-concept for CTI-1601,” sa

Yahoo | November 12, 2021

Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event

BALA CYNWYD, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event. The event is taking place virtually September 22-23, 2021. About Larimar Therapeutics Larimar Therapeutics, Inc. (Nas

Yahoo | September 16, 2021

Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

BALA CYNWYD, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in 1x1 investor meetings at the Morgan Stanley 19th Annual Global Healthcare Conference taking place virtually September 9-15, 2021. Details for the live pre

Yahoo | September 2, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.582 seconds.